loading
Precedente Chiudi:
$0.9293
Aprire:
$0.93
Volume 24 ore:
18.48M
Relative Volume:
1.44
Capitalizzazione di mercato:
$254.62M
Reddito:
$1.21M
Utile/perdita netta:
$-177.12M
Rapporto P/E:
-1.0261
EPS:
-0.8
Flusso di cassa netto:
$-162.37M
1 W Prestazione:
+9.45%
1M Prestazione:
+18.97%
6M Prestazione:
+6.14%
1 anno Prestazione:
-52.82%
Intervallo 1D:
Value
$0.8209
$0.9498
Intervallo di 1 settimana:
Value
$0.7225
$0.97
Portata 52W:
Value
$0.2836
$2.45

Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile

Name
Nome
Lexicon Pharmaceuticals Inc
Name
Telefono
(281) 863-3000
Name
Indirizzo
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Name
Dipendente
103
Name
Cinguettio
@LexPharma
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
LXRX's Discussions on Twitter

Confronta LXRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
LXRX
Lexicon Pharmaceuticals Inc
0.8209 254.62M 1.21M -177.12M -162.37M -0.80
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-05 Downgrade Leerink Partners Outperform → Market Perform
2024-06-17 Iniziato H.C. Wainwright Buy
2024-04-30 Iniziato Leerink Partners Outperform
2023-03-07 Iniziato Jefferies Hold
2022-08-12 Iniziato Piper Sandler Overweight
2021-01-29 Aggiornamento JP Morgan Underweight → Neutral
2021-01-29 Downgrade Wedbush Outperform → Neutral
2020-12-08 Aggiornamento Citigroup Neutral → Buy
2020-11-18 Aggiornamento Gabelli & Co Hold → Buy
2019-12-11 Downgrade Gabelli & Co Buy → Hold
2019-11-08 Downgrade Citigroup Buy → Neutral
2019-09-11 Aggiornamento Gabelli & Co Hold → Buy
2019-07-29 Downgrade Stifel Buy → Hold
2019-03-25 Aggiornamento Gabelli & Co Sell → Hold
2018-07-31 Reiterato Stifel Buy
2018-02-23 Downgrade Needham Buy → Hold
2018-02-14 Downgrade JP Morgan Neutral → Underweight
2017-03-01 Reiterato H.C. Wainwright Buy
2017-03-01 Reiterato Wedbush Outperform
2016-10-07 Iniziato H.C. Wainwright Buy
2016-08-05 Reiterato Wedbush Outperform
2016-08-02 Iniziato Citigroup Buy
2016-03-02 Reiterato Wedbush Outperform
2015-11-09 Reiterato Wedbush Outperform
2015-09-28 Aggiornamento Gabelli & Co Sell → Hold
2015-09-18 Downgrade Gabelli & Co Hold → Sell
2015-08-10 Downgrade JP Morgan Overweight → Neutral
Mostra tutto

Lexicon Pharmaceuticals Inc Borsa (LXRX) Ultime notizie

pulisher
Jun 18, 2025

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) | LXRX Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) - TradingView

Jun 18, 2025
pulisher
Jun 13, 2025

Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31% - simplywall.st

Jun 13, 2025
pulisher
Jun 11, 2025

Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple - MarketScreener

Jun 11, 2025
pulisher
Jun 08, 2025

Lexicon Pharmaceuticals surges 67% following InvestingPro’s Fair Value signal By Investing.com - Investing.com

Jun 08, 2025
pulisher
Jun 05, 2025

Lexicon Pharmaceuticals at Jefferies Conference: Strategic Partnerships and Pipeline Progress - Investing.com Canada

Jun 05, 2025
pulisher
May 30, 2025

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Bought by Northern Trust Corp - Defense World

May 30, 2025
pulisher
May 29, 2025

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times

May 29, 2025
pulisher
May 21, 2025

Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential - MSN

May 21, 2025
pulisher
May 20, 2025

13 Best Multibagger Stocks to Invest in Now - Insider Monkey

May 20, 2025
pulisher
May 19, 2025

Lexicon (LXRX) Advances Study on Sotagliflozin for Heart Conditions | LXRX Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

LXRXLexicon Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan

May 19, 2025
pulisher
May 19, 2025

Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts - simplywall.st

May 19, 2025
pulisher
May 17, 2025

Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st

May 17, 2025
pulisher
May 17, 2025

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance

May 17, 2025
pulisher
May 15, 2025

Lexicon targets late 2025 Phase 3 start for pilavapadin and expands LX9851 partnership with Novo Nordisk - MSN

May 15, 2025
pulisher
May 15, 2025

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 15, 2025
pulisher
May 14, 2025

Lexicon Pharmaceuticals (LXRX) Reports Higher Q1 Revenue and Key Strategic Developments | LXRX Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Lexicon Pharmaceuticals (LXRX) Pre-Earnings Options Activity Rev - GuruFocus

May 14, 2025
pulisher
May 14, 2025

LEXICON PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView

May 14, 2025
pulisher
May 14, 2025

Lexicon Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat

May 14, 2025
pulisher
May 14, 2025

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Bought by Barclays PLC - Defense World

May 14, 2025
pulisher
May 14, 2025

Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlig - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Lexicon: Q1 Earnings Snapshot - New Haven Register

May 14, 2025
pulisher
May 13, 2025

Lexicon Pharmaceuticals (LXRX) Secures Major Licensing Deal with Novo Nordisk - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Lexicon Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:LXRX) - Seeking Alpha

May 13, 2025
pulisher
May 13, 2025

Earnings call transcript: Lexicon Q1 2025 beats EPS expectations, stock declines - Investing.com

May 13, 2025
pulisher
May 13, 2025

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

May 13, 2025
pulisher
May 13, 2025

Lexicon Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025
pulisher
May 13, 2025

Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings: EPS Beats E - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times

May 13, 2025
pulisher
May 13, 2025

Lexicon Pharmaceuticals Q1 Operating Income USD -25.679 Million - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Lexicon Secures Massive $1B Novo Nordisk Partnership While Advancing Breakthrough Pain Drug Trial - Stock Titan

May 13, 2025
pulisher
May 12, 2025

A Preview Of Lexicon Pharmaceuticals's Earnings - Nasdaq

May 12, 2025
pulisher
May 07, 2025

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference - The Manila Times

May 07, 2025
pulisher
May 06, 2025

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference | LXRX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Lexicon Pharmaceuticals Announces Exclusive Fireside Chat at HC Wainwright BioConnect Conference - Stock Titan

May 06, 2025
pulisher
May 06, 2025

Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 - The Manila Times

May 06, 2025
pulisher
May 06, 2025

Lexicon Pharmaceuticals Sets Q1 2025 Earnings Date: Key Financial Updates Coming May 13 - Stock Titan

May 06, 2025
pulisher
Apr 30, 2025

Carcinoid Syndrome Diarrhea Treatment Market To Reach US$ - openPR.com

Apr 30, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 27, 2025

Lexicon Pharmaceuticals, Inc. (LXRX)Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action & Lead Plaintiff Deadline: April 1, 2019 - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 25, 2025

Top 2 Health Care Stocks That May Crash This Month - Benzinga

Apr 25, 2025
pulisher
Apr 22, 2025

Form ARS LEXICON PHARMACEUTICALS, For: Dec 31 - StreetInsider

Apr 22, 2025
pulisher
Apr 09, 2025

Lexicon Pharmaceuticals at Needham Conference: Strategic Shift in Focus By Investing.com - Investing.com Canada

Apr 09, 2025

Lexicon Pharmaceuticals Inc Azioni (LXRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Lexicon Pharmaceuticals Inc Azioni (LXRX) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Sullivan Diane E.
Director
May 13 '25
Option Exercise
0.00
36,810
0
36,810
SOBECKI CHRISTOPHER J
Director
May 13 '25
Option Exercise
0.00
36,810
0
203,865
BARKER SAM L
Director
May 13 '25
Option Exercise
0.00
36,810
0
124,459
Amouyal Philippe
Director
May 13 '25
Option Exercise
0.00
36,810
0
285,174
DEBBANE RAYMOND
Director
May 13 '25
Option Exercise
0.00
36,810
0
1,385,689
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Capitalizzazione:     |  Volume (24 ore):